Enzolytics Will Promote its Nutritional Supplement at ECRM Event Next Week
Industry: Health & Fitness
IPF Immune™, a new Dietary Supplement, Will Participate in an Event With Retail Buyers from Large and Small Retail Chains in the U.S.
Boca Raton, FL (PRUnderground) September 8th, 2022
Enzolytics, Inc., a Texas-based biotech company, will present IPF Immune™, a dietary supplement that supports the immune system, to buyers from large and small retail chains in the U.S. at ECRM’s “Vitamin, Weight Management and Sports Nutrition Program” next week.
“This is an exciting time at Enzolytics because we are making available IPF Immune™, a dietary supplement formulated specifically to support the immune system,” said Charles S. Cotropia, CEO of Enzolytics, Inc. “The buyers at the ECRM event know that consumers are increasingly aware of the importance of maintaining a healthy immune system.”
ECRM brings buyers and brands with new products together for private meetings. Buyers attending the ECRM event represent regional and national food, drug, and mass chains.
Although sales of supplements skyrocketed during the pandemic, nutritional supplements are expected to still see strong numbers in 2022.
“We expect the buyers to be on the lookout for new and effective products,” he added. ” More Americans are buying dietary supplements than ever before, which is another reason the buyers should be interested in our product.”
IPF Immune™ is a dietary supplement that supports the body’s immune system by promoting normal immune function, which is critical to good health.
Enzolytics IPF Immune™, which is gluten-free, is a nutritional supplement that is taken orally two consecutive days per week for eight consecutive weeks.
“We have developed a dietary supplement that people want and need,” Mr. Cotropia said. “We are looking to add as many retail outlets as we can. ECRM gives us an excellent opportunity to meet dozens of buyers in less than a week.”
For more information, email pr@nutrapr.com or visit enzolytics.com.
Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. The news site hosting this press release is not associated with Enzolytics, Inc. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.
Company Contact:
Enzolytics, Inc.
Research Center
Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-44
SOURCE: Enzolytics, Inc.
About Enzolytics, Inc.
Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune™, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases.
